Abstract:Abstract From the clinical standpoint, systemic sclerosis (SSc) is characterized by skin and internal organ fibrosis, diffuse fibroproliferative vascular modifications, and autoimmunity. Clinical presentation and course are highly heterogenous and life expectancy variably affected mostly dependent on lung and heart involvement. SSc touches more women than men with differences in disease severity and environmental exposure. Pathogenetic events originate from altered homeostasis favored by genetic predisposition, environmental cues and a variety of endogenous and exogenous triggers. Epigenetic modifications modulate SSc pathogenesis which strikingly associate profound immune-inflammatory dysregulation, abnormal endothelial cell behavior, and cell trans-differentiation into myofibroblasts. SSc myofibroblasts show enhanced survival and enhanced extracellular matrix deposition presenting altered structure and altered physicochemical properties. Additional cell types of likely pathogenic importance are pericytes, platelets, and keratinocytes in conjunction with their relationship with vessel wall cells and fibroblasts. In SSc, the profibrotic milieu is favored by cell signaling initiated in the one hand by transforming growth factor-beta and related cytokines and in the other hand by innate and adaptive type 2 immune responses. Radical oxygen species and invariant receptors sensing danger participate to altered cell behavior. Conventional and SSc-specific T cell subsets modulate both fibroblasts as well as endothelial cell dysfunction. Beside autoantibodies directed against ubiquitous antigens important for enhanced clinical classification, antigen-specific agonistic autoantibodies may have a pathogenic role. Recent studies based on single-cell RNAseq and multi-omics approaches are revealing unforeseen heterogeneity in SSc cell differentiation and functional states. Advances in system biology applied to the wealth of data generated by unbiased screening are allowing to subgroup patients based on distinct pathogenic mechanisms. Deciphering heterogeneity in pathogenic mechanisms will pave the way to highly needed personalized therapeutic approaches.

Mitochondria, Aging, and Cellular Senescence: Implications for Scleroderma

Role of cellular senescence in the pathogenesis of systemic sclerosis

Molecular Basis of Accelerated Aging with Immune Dysfunction-Mediated Inflammation (Inflamm-Aging) in Patients with Systemic Sclerosis

Sirtuins and Accelerated Aging in Scleroderma

Recent Insights into Cellular and Molecular Mechanisms of Defective Angiogenesis in Systemic Sclerosis

Senescence and tissue fibrosis: opportunities for therapeutic targeting

The role of extracellular matrix components in angiogenesis and fibrosis: Possible implication for Systemic Sclerosis

Gene expression meta-analysis reveals aging and cellular senescence signatures in scleroderma-associated interstitial lung disease

Current Concepts on the Pathogenesis of Systemic Sclerosis

Distinct Metalloproteinase Expression and Functions in Systemic Sclerosis and Fibrosis: What We Know and the Potential for Intervention

Mitochondrial Dysfunction: A Roadmap for Understanding and Tackling Cardiovascular Aging.

Cellular Senescence: The Driving Force of Musculoskeletal Diseases

Pathophysiology of systemic sclerosis (scleroderma)

Molecular Mechanisms, Pathogenetic Role and Therapeutic Opportunities

Systemic Sclerosis and Atherosclerosis: Potential Cellular Biomarkers and Mechanisms

Vascular hypothesis revisited: Role of stimulating antibodies against angiotensin and endothelin receptors in the pathogenesis of systemic sclerosis

The Epigenetic Regulation of Scleroderma and Its Clinical Application

Advances in epigenetics in systemic sclerosis: molecular mechanisms and therapeutic potential

Immune Cell Dysregulation As a Mediator of Fibrosis in Systemic Sclerosis

Pathogenic Roles of Autoantibodies and Aberrant Epigenetic Regulation of Immune and Connective Tissue Cells in the Tissue Fibrosis of Patients with Systemic Sclerosis

Unfolding the Pathogenesis of Systemic Sclerosis Through Epigenomics